You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a blood test for breast cancer detection

    SBC: INTEGRATED TECHNOLOGIES AND SRVCS INTRNTL            Topic: N/A

    DESCRIPTION (provided by applicant): Mammography is the benchmark for breast disease detection and diagnosis. However, it can miss 10-15% of early stage breast cancers, and it is unable to distinguish between benign and malignant lesions with certainty. Av ailability of an alternate method e.g. biomarker based, which allows early detection/precise distinction between benign disease and breast canc ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Sphingosine Kinase Inhibitors as Anti-Arthritis Agents

    SBC: Apogee Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Sphingolipids are being increasingly recognized as key mediators of inflammatory cascades of critical importance in multiple diseases, including rheumatoid arthritis and osteoarthritis. Most importantly, sphingosine 1-phosphate produced by sphingosine kinase (SK) mediates the effects of tumor necrosis factor-1 and interleukin-12, pro-inflammatory cytokines ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents

    SBC: Apogee Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents for retinal and choroidal vascular diseases. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development of new drugs for the treatment of ocular diseases assoc ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  4. 18F-FP-DTBZ for PET Imaging of Beta Cell Mass in Diabetes

    SBC: AVID RADIOPHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Both Type I (T1D) and Type 2 (T2D) diabetes share a common pathophysiology - insufficient beta cell mass (BCM) to meet metabolic demands. Unfortunately, advances in diabetes are slowed by a lack of reliable methods to measure BCM in vivo. The ability to accurately track BCM would facilitate development and clinical evaluation of therapies to preserve or replace ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Radiopharmaceuticals for Imaging Brain Tau Pathology

    SBC: AVID RADIOPHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with more than 4.5 million Americans currently suffering from the disease. Clinical management of AD is complicated by lack of effective meth ods for early and accurate diagnosis of the disease. Thus, there is a significant unmet need for Alzheimer's disease diagnostic tools. The hypo ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. 18F-AV-133, A Novel Radiopharmaceutical for Differential Diagnosis of Dementia

    SBC: AVID RADIOPHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Dementia, with its most prevalent subforms Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and vascular dementia, is a very substantial medical and societal problem. The emergence of many drugs and drug can didates that interfere with the disease mechanism of specific types of dementia makes it crucial to distinguish early between the various forms ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. 18F-AV-45 PET Imaging of Amyloid in PD with Cognitive Impairment

    SBC: AVID RADIOPHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Dementia associated with PD (PDD) is common (affecting up to 80% of patients long-term) and highly disabling. Informative biomarkers are urgently needed to understand the pathology of PDD, to improve the early detection of cognitive deficits and to facilitate the development of treatments for PDD. Nuclear imaging technologies have the potential to produce such ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Nanochannel Devices for High Throughput Single Molecule DNA mapping and Haplotypi

    SBC: BIONANOMATRIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long term objective of this proposal is to develop a fully integrated nanochannel chip and reader capable of single molecule mapping of linearized, long genomic material. The anticipated embodiment will permit dire ct visualization and analysis of megabase fragments of DNA extracted directly from a sample (possibly a single cell) with sub-kilobase resoluti ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. ShoulderNav: Computer Assisted Total Shoulder Arthroplasty

    SBC: BLUE BELT TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): About 4 million people in the U.S. seek medical care each year for shoulder problems, with shoulder arthritis as one of the most common. Shoulder replacement surgery, also called total shoulder arthroplasty or "TSA", is often the only effective treatment for the severe, unrelenting pain that affects these patients. TSA is a difficult surgical procedure, which r ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Design and development of a bioresorbable bone graft

    SBC: CarMell Therapeutics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe, cost-effective, off-the-shelf, and well characterized bone filler material based on plastics derived from blood byproducts. Over 800,000 bone procedures are perfo rmed in the US per year, and with the aging US population, this number will only continue to grow. However, current materials, including autogr ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government